Shares of Sage Therapeutics, Inc. ( NASDAQ:SAGE – Get Rating ) have earned a consensus rating of 'Hold' from the fifteen analysts that are currently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $51.83. A number of analysts recently weighed in on SAGE shares. Needham & Company LLC restated a 'buy' rating and issued a $70.

https://www.dailypolitical.com/2023/05/30/analysts-set-sage-therapeutics-inc-nasdaqsage-price-target-at-52-83.html

#dailypolitical